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ABSTRACT 38 
Background: Streamlining the timing of treatments in Cystic Fibrosis (CF) is important to 39 
optimise adherence whilst ensuring efficacy. The optimal timing of treatment with hypertonic 40 
saline (HTS) and airway clearance techniques (ACT) is unknown. 41 
Objectives: This study hypothesised that HTS before ACT would be more effective than 42 
HTS during ACT as measured by lung clearance index (LCI).  43 
Methods: Adults with CF providing written informed consent were randomised to a 44 
crossover trial of HTS before ACT or HTS during ACT on consecutive days. ACT treatment 45 
consisted of Acapella® Duet. Patients completed LCI and spirometry at baseline and 90 46 
mins post treatment. Sputum was collected immediately post treatment. Patient perception 47 
of ease of clearance and satisfaction with treatment was recorded. Wilcoxon test was used 48 
and p<0.05 was considered significant.  49 
Results: Fourteen subjects were recruited and 13 completed the study (mean [SD] age 33 50 
[12] years, FEV1% predicted 51% [22], LCI (no. turnovers) 14 [4]). Comparing the two 51 
treatments (HTS before ACT vs HTS during ACT), the change from baseline to 90 mins post 52 
treatment in LCI (p=0.70) and FEV1% predicted (p=0.97) was not significant. There was no 53 
difference in sputum weight (p=0.31), patient perceived ease of clearance (p=0.56) or 54 
satisfaction (p=0.48). The time taken for HTS during ACT was significantly shorter (p=0.002). 55 
Conclusions: In this pilot study, HTS before ACT was no more effective than HTS during 56 
ACT as measured by lung clearance index (LCI). 57 
 58 
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Introduction 75 
There is clear evidence that airway clearance techniques (ACT) to improve mucus clearance 76 
should form part of treatment in Cystic Fibrosis (CF)(1-4) and emerging evidence that some 77 
forms of ACT may be more effective in the long-term(5). Quality of evidence in this area is 78 
variable highlighting the need for high quality trials in the future to provide a more robust 79 
evidence base for treatment. Often, technique choice remains dependent on patient 80 
preference and convenience as well as age and stage of disease(5-7). Recent research 81 
strategy has shifted from examining the comparative efficacy of different ACT to the study of 82 
ways to optimise the application of techniques(6). Finding the optimal treatment for a patient 83 
at any specific time requires consideration of available research evidence on efficacy 84 
amongst a range of other factors including coordination with inhaled therapies(8). Some 85 
forms of ACT now offer the possibility to deliver inhaled therapies during treatment and 86 
whilst these devices are attractive in terms of reducing the time burden associated with 87 
treatment it is unclear how the timing of inhaled therapies impact on the effectiveness of 88 
ACT. Mucoactive agents such as hypertonic saline (HTS) are recommended to facilitate 89 
mucocilary clearance based on clear evidence from high quality clinical trials across the age 90 
range and disease trajectory in CF(9-14). These trials typically administered HTS before 91 
ACT and this is currently the clinical recommendation. Notably, some technologies to deliver 92 
HTS during ACT were not available when these trials were conducted and further studies of 93 
these methods may yield useful results.   94 
A recent Cochrane review highlighted how clinical effect could be influenced by the 95 
timing of HTS delivery in relation to ACT. The review outlined a number of potential 96 
theoretical benefits to inhalation of HTS during airway clearance, including maximising the 97 
benefits of the immediate peak in the airway surface liquid volume and reduced treatment 98 
time(15). Following this review, a randomised controlled trial of 50 adult CF patients 99 
assessed the change in lung function (FEV1% predicted) and perceived effectiveness and 100 
satisfaction of 3 treatment regimens (HTS before, during and after ACT) at the end of a 101 
hospital admission(16). This study found that effects on FEV1 were not significant. 102 
Satisfaction was rated significantly worse when HTS was inhaled after ACT compared to 103 
before or during ACT. Perceived effectiveness of treatment showed similar effects. The 104 
study concluded that people with CF should be encouraged to time HTS before or during 105 
ACT to maximise perceived efficacy and satisfaction. There are currently no data on the 106 
effect of HTS and ACT timing on the Lung Clearance Index (LCI). LCI provides an 107 
assessment of ventilation distribution as measured by Multiple Breath Washout (MBW) 108 
which is increasingly being used in CF interventional studies(17). It is established that FEV1 109 
lacks sufficient sensitivity to detect changes in the peripheral airways(18). LCI has shown 110 
greater sensitivity to abnormalities in lung function compared with spirometry across the age 111 
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ranges in CF(19,20) and has proven responsiveness in trials of inhaled therapies(21,22) and 112 
ACT(23) in CF. Importantly, significant improvements in LCI have been reported with 113 
relatively small numbers of patients (n=17-25)(14,21,22,24). These studies support the 114 
exploration of the effects of ACT in CF using LCI. 115 
This pilot study aimed to compare the change in LCI at 90 minutes post treatment 116 
with HTS inhalation before ACT compared with HTS inhalation during ACT in adult CF 117 
patients. Secondary outcomes included the change in FEV1% predicted, FEF25-75% 118 
predicted, 24 hour sputum volumes, patient and physiotherapist perceived ease of clearance 119 
and satisfaction with treatment, number of coughs and duration of treatment.  120 
 121 
METHOD   122 
Subject recruitmentInclusion criteria for the study was subjects with CF aged ≥18 years, 123 
near the end of an intravenous antibiotic (IVAB) therapy course (days 10-14) for a pulmonary 124 
exacerbation at Belfast Health and Social Care Trust (BHSCT), who were productive of 125 
sputum ≥10g over 24 hours on enrolment, currently uses or had previously used and 126 
tolerated HTS (Nebusal™ 7%) and provided written informed consent. The exclusion criteria 127 
was subjects who are HTS naïve, had a reported intolerance to HTS, currently participating 128 
in another study or have participated in another study with an investigational drug within one 129 
month of screening, or had a clinically significant condition other than CF or CF-related 130 
conditions that could compromise the safety of the patient or the quality of the data. 131 
Subjects were recruited between December 2012 and January 2015. This study was 132 
approved by the Office for Research Ethics Committees Northern Ireland (REC reference 133 
number 12/NI/0153), sponsored by Belfast Health and Social Care Trust (reference number: 134 
12025JB-AS) and registered with clinical trials.gov (reference number NCT01753869). 135 
 136 
Treatment 137 
Subjects were randomised to complete crossover treatment of HTS before ACT inhalation 138 
(treatment order A) and HTS inhalation during ACT (treatment order B) on consecutive days. 139 
The ACT chosen was the Acapella® (Acapella® Duet Vibratory PEP Therapy System, 140 
Portex®, Smith medical) which allowed for HTS inhalation during treatment. Both subjects 141 
who were Acapella® naive and subjects who had previous experience of using Acapella® 142 
were included. Randomisation was electronically generated and concealed by an 143 
administrator independent of the study. Treatment was assigned and carried out by a 144 
qualified respiratory physiotherapist (F.M, J.M.B, K. McD). Full details for each treatment 145 
order are presented in Table 1. The assessor conducting the outcome measures (K O’N) 146 
was blinded to the treatment intervention order.  147 
 148 
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Table 1: Treatment order details 149 
 150 
Treatment order Detail 
Treatment order A:  
HTS before ACT 
 Bronchodilator (Salbutamol 200mcg), 
 Wait 15 minutes,  
 Single inhalation (4mls) of 7% HTS (Nebusal™) via 
updraft nebuliser (Portex) (approx 20 minutes), 
 Immediately followed by an airways clearance 
session of 10 supervised cycles using the Acapella® 
and forced expiration techniques (approx 20 mins). 
Treatment order B:  
HTS during ACT 
 Bronchodilator (Salbutamol 200mcg), 
 Wait 15 minutes,  
 Single inhalation (4mls) of 7% HTS (Nebusal™) 
through the Acapaella® Duet (with Portex updraft 
nebuliser attached) device. 
 During inhalation, an airways clearance session of 10 
supervised cycles using the Acapella® and forced 
expiration techniques was carried out (approx 20 
mins). 
 151 
Detailed content of the supervised cycles using the Acapella® is provided in online 152 
supplement 1. Subjects received the treatments at the same time each day, in the same 153 
position (high sitting) and the treatment duration was recorded. 154 
 155 
OUTCOME MEASURES 156 
Lung Clearance Index 157 
The Multiple Breath Washout (MBW) test to measure LCI was carried out using the modified 158 
InnocorTM device and 0.2% sulfur hexafluoride (SF6) using the previously validated open-159 
circuit technique in accordance with the standard operating procedure (online supplement 2) 160 
(25). Subjects breathed through a mouthpiece at normal tidal volumes, whilst in a seated 161 
position and wearing a nose clip. Analysis of MBW data was performed using the Simple 162 
Washout programme (permission granted). Functional residual capacity (FRC) was 163 
calculated as part of the LCI equation (LCI=Cumulative expired volume/FRC). LCI 164 
represents the number of FRC lung volume turnovers it takes to clear the inert gas (SF6) 165 
from the lungs and quantifies the degree of uneven gas mixing throughout the lungs. MBW 166 
was performed before, immediately after and 90 minutes after the treatment intervention. 167 
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Ninety minutes was considered the longest period that was reasonable for a subject to wait. 168 
MBW was carried out either before or at least 30 minutes after spirometry in order to avoid 169 
any effects of forced breathing manoeuvre on LCI.  170 
 171 
Spirometry 172 
Spirometry was measured according to ATS/ERS guidelines (26) using a Microlab (ML3500 173 
MK8) spirometer (CareFusion, Kent, UK). FEV1 % predicted and FEF35-75% predicted values 174 
were calculated from reference ranges for all ages (27) 175 
 176 
Sputum wet weight 177 
Wet weight sputum (g) expectorated immediately after each treatment session and total wet 178 
weight sputum expectorated in the 24 hours following the start of each study visit was 179 
collected in pre-weighed containers and recorded (Metter J Balance, Meter-Toledo, 180 
Switzerland).  181 
 182 
Patient and physiotherapist perceived ease of clearance and satisfaction 183 
Subjects and the physiotherapist delivering the treatment intervention scored their perceived 184 
ease of sputum clearance and level of satisfaction with each treatment using a visual 185 
analogue scale labelled from 0 to 100 (0 represented not easy/not satisfied, 100 represented 186 
extremely easy/extremely satisfied) (online supplement 3). 187 
 188 
Cough count 189 
During each treatment session, the physiotherapist performed a manual “cough count” 190 
recording the number of coughs per treatment session.  191 
 192 
Statistical analysis  193 
For the primary endpoint of change in LCI at 90 minutes post treatment, a sample size of 194 
n=31 was estimated to detect a treatment effect size of 1.5 assuming a significance level of 195 
5% and a power of 80%. An interim analysis was planned at the half way point. Data was 196 
summarised using mean (SD) or median (IQR) statistics as appropriate. Wilcoxon test and 197 
McNemar’s test was used to assess change in the variables of interest. Treatment effect 198 
size was calculated as z/square root of N (number of observations). A p-value <0.05 was 199 
considered statistically significant.  200 
 201 
RESULTS 202 
Following an interim analysis to compare change in LCI at 1% alpha in data from 13 203 
subjects, results showed the treatment effect was unlikely to be sufficiently large to attain 204 
7 
 
clinical or statistical significance. Given this and challenges with recruitment, the decision 205 
was made to terminate the study at this point. These study results are presented as pilot 206 
data to inform future studies.207 
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Fourteen subjects were recruited and 13 completed the study. Figure 1 illustrates the 208 
flowchart of recruitment. Table 2 present’s subject baseline characteristics.  209 
 210 
Table 2: Subject baseline characteristics (n=13) 211 
Baseline characteristics   
Age (years) 33.2 (12.2) 
Female/Male 5:8 
Median (IQR) 24 hour sputum weight (g) 20.0 (25.0) 
FEV1 % predicted 51.1 (22.0) 
Median (IQR) FEF25-75 % predicted 14.0 (38.0) 
LCI (no. turnovers) 13.9 (3.7) 
Mean (SD) unless otherwise stated 212 
 213 
Within treatment change 214 
The change in LCI from baseline to 90 minutes post treatment with HTS before ACT 215 
(p=0.75) or with HTS during ACT (p=0.49) was not significant (Table 3 and Figure 2 a and 216 
b).  The FRC (component of the LCI) was significantly reduced with HTS during ACT 217 
treatment (p=0.04), but was unchanged with HTS before ACT treatment (p=0.27). With ACT 218 
after HTS, the mean (SD) change in LCI was -0.1 (1.1) lung turnovers; 8/13 patients 219 
worsened (i.e. LCI increased) and 5/13 patients improved (i.e. LCI decreased). With HTS 220 
during ACT, the mean (SD) change in LCI was -0.1 (0.9) lung turnovers; 7/13 worsened (i.e. 221 
LCI increased) and 6/13 improved (i.e. LCI decreased). Change in LCI from baseline to 222 
immediately after treatment with HTS before ACT (p=0.48) or with HTS during ACT (p=0.65) 223 
was also not significant (data not shown).   224 
Considering the secondary outcome measures, the change in FEV1 (after 90 225 
minutes) with HTS before ACT bordered on significance (p=0.05) with a medium treatment 226 
effect (r=0.38) (Table 3 and e-Figure 3a). The mean (SD) change was 1.4% (3.3); 10/13 227 
improved (i.e. FEV1 increased), 2/13 worsened (i.e. FEV1 decreased) and 1/13 stayed the 228 
same. With HTS during ACT, the mean (SD) change in FEV1 of 1.6% (4.5) was also not 229 
significant (p=0.14); 7/13 patients improved (i.e. FEV1 increased), 4/13 worsened (i.e. FEV1 230 
decreased) and 2/13 stayed the same (Table 3 and e-Figure 3b). There was also no 231 
significant change in FEF35-75% predicted with either treatment (Table 3 and e-Figures 4 a 232 
and b). 233 
 234 
Between treatment change  235 
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Comparing the two treatments (HTS before ACT vs HTS during ACT), the change from 236 
baseline to immediately post treatment in LCI (p=0.72) and the change from baseline to 90 237 
minutes post treatment in LCI (p=0.70), FEV1% predicted (p=0.97) and FEF35-75% predicted 238 
(p=0.45) was not significantly different. 239 
With both treatment orders, the change in LCI and change in FEV1% predicted at 90 240 
minutes post treatment was not always in agreement. With HTS before ACT, LCI and 241 
FEV1% predicted results were in agreement in 7/13 subjects (54%) (r=-0.51; p=0.08). With 242 
HTS during ACT, LCI and FEV1 results were in agreement in 10/13 (77%) subjects (r=-0.48; 243 
p=0.10). 244 
Comparing the two treatments (HTS before ACT vs. HTS during ACT) using the 245 
other study endpoints, there was no difference in sputum weight expectorated immediately 246 
post (p=0.31) or 24 hours post (p=0.12) treatment, patient perceived ease of clearance 247 
(p=0.56) or satisfaction (p=0.48). There was also no difference in the physiotherapist 248 
perception of the ease of clearance (p=0.08), physiotherapist perception of the satisfaction 249 
with treatment (p=0.29) or in the number of coughs recorded (p=0.09) between treatments. 250 
The time taken for HTS during ACT was significantly shorter (p=0.002) equating to a mean 251 
difference of 15 minutes (e-Table 4). 252 
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Table 3: LCI and spirometry before and after treatment  
 HTS before ACT (n=13) HTS during ACT (n=13) 
Baseline Post MD (95% 
CI) 
Rx effect p value Baseline Post MD (95% 
CI) 
Rx effect  p value 
Mean (SD) LCI (no. 
turnovers) 
14.1 (3.6) 14.2 (3.6) 0.10 (-0.59 
to 0.79) 
0.06 0.75 13.8 (3.4) 13.9 (3.6) 0.12 (-0.42 
to 0.66) 
0.14 0.49 
Mean (SD) FRC (L) 2.24 (0.5) 2.18 (0.5) -0.55  
(-0.17 to 
0.06) 
0.22 0.27 2.20 (0.5) 2.09 (0.5) -0.11 (0.20 
to 0.03) 
0.40 0.04* 
Mean (SD) FEV1 % 
predicted 
47.2 (18.9) 48.6 (18.3) 1.38 (-0.61 
to 3.38) 
0.38 0.05 47.2 (18.2) 48.8 (19.4) 1.64 (-1.06 
to 4.34) 
0.29 0.14 
Mean (SD) FEF25-75 % 
predicted 
25.2 (27.5) 26.8 (26.9) 1.54 (-1.41 
to 4.48) 
0.26 0.18 23.9 (25.6) 27.4 (25.4) 3.46 (-2.80 
to 9.72) 
0.31 0.11 
*p<0.05 
LCI lung clearance index; FRC functional residual capacity; FEV1%predicted forced expiratory volume in one second; FEF25-75% predicted 
forced expiratory flow 25-75; HTS hypertonic saline; ACT airway clearance treatment
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DISCUSSION AND CONCLUSIONS 
As technology advances, more efficient ways of delivering inhaled therapies linked to ACT 
are being explored in an effort to reduce the treatment time required. This pilot study aimed 
to explore the effectiveness of one such strategy, HTS during ACT using the Acapella® 
Duet.   
This pilot study found that the timing of HTS in relation to ACT did not have a 
significant effect on the change in LCI after a single treatment session.  Although HTS during 
ACT was significantly shorter in duration, secondary endpoints of spirometry, sputum 
volumes, patient and physiotherapist perception of ease and satisfaction, and number of 
coughs were also not significantly different between treatments.  
These results are in agreement with the findings by Dentice and colleagues(16), who 
found no difference in lung function between regimens (HTS before, during or after ACT) 
and reported similar numbers of patients stating a preference for ACT after or during HTS, 
compared with ACT before HTS. The authors concluded that preference for HTS before or 
during ACT over HTS after ACT, could have implications for long-term adherence. The pilot 
data presented in this paper adds to this topic further exploring differences between HTS 
before or during ACT regimens. Results suggest that if length of treatment time is an issue 
affecting adherence, HTS during ACT may offer a regimen which is equally effective but of 
shorter duration. Furthermore, although not statistically significant, notably fewer coughs 
were required to expectorate the same volume of sputum with ACT during HTS treatment 
compared to the HTS before ACT treatment. 
Importantly, these results indicate that as a novel endpoint, LCI did not offer any 
further information in response to ACT and HTS treatment compared with spirometry.  FEV1 
is not always a suitable outcome measure for ACT trials due to its lack of sensitivity as an 
endpoint(28). LCI was chosen as the primary outcome measure in this study as it has 
demonstrated superior sensitivity to changes in disease compared to spirometry(20) and has 
proven responsiveness to treatment effect with inhaled therapies(14,21,22) and ACT(23) in 
CF. However, in this study, LCI did not detect any change within or between treatments. 
Change in LCI also did not significantly correlate with FEV1, with either treatment. Studies by 
Fuchs and colleagues and Pfleger and colleagues have also reported small and inconsistent 
(increasing and decreasing) changes in LCI after physiotherapy with weak to modest 
correlations between change in LCI and FEV1(29,30). Results from this pilot study of 
patients primarily with moderate to severe lung disease, add to this data providing results 
from two time points (immediately post and 90 minutes post treatment) from a clearly defined 
intervention (inhaled therapy and ACT). The change in FRC as a component of LCI with 
HTS during ACT treatment was significantly decreased, but this did not translate to a change 
in LCI. These results suggest that the effects of sputum clearance on LCI and FRC are 
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complex, as ACT may open previously completely obstructed airways resulting in the 
recruitment of lung units paradoxically increasing LCI. LCI may also be much less 
informative in those with significant airflow obstruction(31,32) which made up a large 
proportion of patients in this study (8/13 FEV1 <50% predicted at baseline). Discordant 
results with LCI and FEV1 may not be surprising as they each measure a different aspect of 
lung physiology. These results add to the argument that LCI may not be a suitable short term 
endpoint for airways clearance trials as response is unpredictable. Previous studies 
reporting significant effects assessed treatment effect were not short term but over a period 
4 – 48 weeks with inhaled therapies(14,21,33) and 3 months with airways clearance 
therapy(23). Lack of overall change in LCI in this study was in agreement with other 
endpoints including spirometry, sputum weight and patient preference supporting the validity 
of these results. The change in FEV1 from baseline to 90 minutes post treatment (with HTS 
before ACT) was borderline (p=0.05), equating to a +1.4% change, although clinically this 
could not be considered significant. 
Wet-weight sputum was chosen as a secondary outcome measure as it is feasible to 
perform. However, we acknowledge the inherent limitations of this measure as a clinical trial 
endpoint. Expectorated weight weight sputum can include saliva, introducing error. An 
increase of decrease in sputum can be interpreted as an improvement i.e. an increase may 
mean improvement in clearance or a decrease may mean a resolution in infection. These 
issues limit the use of sputum as a reliable trial endpoint, although it remains an endpoint 
that is meaningful to patients 
In this study, in-patients receiving IVAB for treatment of a pulmonary exacerbation 
were the target group for recruitment. This was for feasibility reasons as the study design 
involved treatment on two consecutive days which would likely have been prohibitive for out-
patients. Although our study design aimed to ensure participants were as close to their 
stable status as possible (days 10-14 IV antibiotics), our recruitment process demonstrated 
how some patients were still unwell at this time point (i.e. 2 patients failed screening as they 
felt too unwell to proceed; Figure 1) and we cannot completely rule out the effect of 
pulmonary exacerbation on the variability of lung function results(31). However, this study 
represents a “real-life” evaluation of a treatment that is often carried out during hospital 
admission.  
This study investigated the use of a less commonly used adjunct (Acapella Duet) 
through which to deliver HTS during ACT. Using this device, we did not observe any 
significant deposition of HTS directly in the device and the resistance levels achieved 
remained optimum (between 10-20 cmH20) in both treatments. Limitations of this study 
include the small sample size and findings need to be reproduced in a larger sample, 
therefore the conclusions must be interpreted with caution. Recruitment was challenging due 
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to inclusion criteria in the study which required that subjects had previously taken and 
tolerated HTS and be productive of > 10g of sputum at the end of IVAB treatment. Of the 
subjects who met the criteria, the majority progressed to screening (20/32; 63%) and 
thereafter randomisation (14/20; 70%). Opening the study to out-patients could have 
increased the number of potentially eligible patients, however adherence to the study design 
(attendance on 2 consecutive days) we believe would have been challenging.  
However, this pilot study is the first study to assess the effect of HTS and ACT timing 
using LCI as an outcome measure and employed rigorous study design including blinded 
outcome measure assessor and a broad range of measures.  
Overall, the results from this pilot study could not support the hypothesis that HTS 
before ACT was more effective than HTS during ACT as measured by LCI. Results indicate 
that HTS during ACT was no more effective than HTS before ACT, although it did result in a 
shorter treatment duration.  
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